U.S. dermatology drugs market is projected to register a CAGR of 8.2% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.
Market Segmentation:
U.S. dermatology drugs market is categorized into seven notable segments which are based on the basis of drug class (corticosteroids, retinoids, monoclonal antibodies, antibiotics agent, antiviral agents, antifungal drugs, antihistamines agents, immunosuppressive drugs and others), drug type (branded and generics), prescription mode (prescription based drugs and over-the-counter drugs), indication (infectious skin disease, inflammatory/autoimmune disorders, pigmentation disorders, skin cancer and others), route of administration (topical, oral, parenteral), end user (homecare, hospitals, dermatology clinics and others) and distribution channel (retail pharmacy, hospitals pharmacy, online pharmacy and others).

Some of the major factors contributing to the growth of the market are:
- Increasing advancements in the drug
- Growing awareness for skin care

Market Players:
The key market players for U.S. dermatology drugs market are listed below:

- Novartis AG
- Pfizer Inc.
- Eli Lilly and Company.
- Johnson & Johnson Services, Inc.
- Almirall, S.A
- Mylan N.V.
- Sun Pharmaceutical Industries Ltd.
- UCB S.A. Belgium
- Glenmark Pharmaceuticals Limited
- Tolmar Pharmaceuticals, Inc.
- GlaxoSmithKline plc.
- Galderma Laboratories, L.P.
- Teva Pharmaceutical Industries Ltd.
- LEO Pharma A/S
- Melinta Therapeutics, INC. - THE Antibiotics Company
- Mayne Pharma Group Limited
- Biofrontera AG
- AbbVie Inc.